NO20054453L - P38 inhibitorer og fremgangsmater for anvendelse derav - Google Patents
P38 inhibitorer og fremgangsmater for anvendelse deravInfo
- Publication number
- NO20054453L NO20054453L NO20054453A NO20054453A NO20054453L NO 20054453 L NO20054453 L NO 20054453L NO 20054453 A NO20054453 A NO 20054453A NO 20054453 A NO20054453 A NO 20054453A NO 20054453 L NO20054453 L NO 20054453L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/378,164 US7135575B2 (en) | 2003-03-03 | 2003-03-03 | P38 inhibitors and methods of use thereof |
US10/688,849 US20040180896A1 (en) | 2003-03-03 | 2003-10-15 | P38 inhibitors and methods of use thereof |
PCT/US2004/005693 WO2004078116A2 (en) | 2003-03-03 | 2004-02-25 | P38 inhibitors and methods of use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20054453D0 NO20054453D0 (no) | 2005-09-26 |
NO20054453L true NO20054453L (no) | 2005-11-29 |
NO328913B1 NO328913B1 (no) | 2010-06-14 |
Family
ID=32965317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054453A NO328913B1 (no) | 2003-03-03 | 2005-09-26 | P38-inhibitorer, deres anvendelse og farmasoytiske sammensetninger omfattende forbindelsene |
Country Status (12)
Country | Link |
---|---|
US (1) | US7521447B2 (no) |
EP (1) | EP1606283B1 (no) |
JP (1) | JP4617299B2 (no) |
KR (1) | KR101099281B1 (no) |
AU (1) | AU2004218463B2 (no) |
CA (1) | CA2517517C (no) |
IS (1) | IS2675B (no) |
MX (1) | MXPA05009459A (no) |
NO (1) | NO328913B1 (no) |
PL (1) | PL214032B1 (no) |
RU (1) | RU2357957C2 (no) |
WO (1) | WO2004078116A2 (no) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050071598A (ko) * | 2002-10-24 | 2005-07-07 | 메르크 파텐트 게엠베하 | 라프-키나아제 억제제로서의 메틸렌 우레아 유도체 |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
MXPA06002853A (es) * | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
CN1882347A (zh) | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
JP2007523936A (ja) | 2004-02-27 | 2007-08-23 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロアリール縮合ピラゾロ誘導体 |
PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
MX2007003603A (es) * | 2004-11-02 | 2007-05-21 | Pfizer | Metodos para preparar compuestos de indazol. |
WO2006048744A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods of preparing indazole compounds |
CN101052633A (zh) * | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
EP1883404A4 (en) * | 2005-05-11 | 2010-03-31 | Array Biopharma Inc | P38 INHIBITORS AND METHODS OF USE |
CA2620104A1 (en) | 2005-08-25 | 2007-03-01 | F. Hoffman-La Roche Ag | Fused pyrazole as p38 map kinase inhibitors |
JP2009506006A (ja) * | 2005-08-25 | 2009-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | p38MAPキナーゼ阻害剤およびその使用方法 |
BRPI0615442A2 (pt) | 2005-08-25 | 2011-05-17 | Hoffmann La Roche | inibidores de p38 map cinase e métodos para uso dos mesmos |
EP1931668A2 (en) * | 2005-09-16 | 2008-06-18 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
CA2927656C (en) | 2005-10-07 | 2019-09-24 | Exelixis, Inc. | Mek inhibitors and methods of their use |
CN101331120A (zh) * | 2005-10-13 | 2008-12-24 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体调节剂的酚醚化合物 |
AU2006315436A1 (en) * | 2005-11-15 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
EP1970375A4 (en) * | 2005-11-29 | 2010-06-02 | Toray Industries | ARYLMETHYLENE UREE DERIVATIVE AND USE THEREOF |
CA2635813C (en) * | 2006-01-31 | 2014-01-07 | Array Biopharma, Inc. | Urea derivatives as kinase inhibitors and methods of use thereof |
CN101454313A (zh) * | 2006-03-29 | 2009-06-10 | 阿雷生物药品公司 | P38抑制剂及其使用方法 |
WO2008042973A2 (en) * | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
EP2101759B1 (en) * | 2006-12-14 | 2018-10-10 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008076446A1 (en) * | 2006-12-18 | 2008-06-26 | Coleman Peter R | Accelerated opiate dependence detoxification process |
WO2008074676A1 (en) * | 2006-12-19 | 2008-06-26 | F. Hoffmann-La Roche Ag | Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors |
US8114865B2 (en) * | 2006-12-20 | 2012-02-14 | Nerviano Medical Sciences S.R.L. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US8202899B2 (en) * | 2007-07-25 | 2012-06-19 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
CA2730397A1 (en) * | 2008-07-15 | 2010-01-21 | F.Hoffmann-La Roche Ag | Substituted indolyl and indazolyl derivatives and uses thereof |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
EA020641B1 (ru) | 2008-10-02 | 2014-12-30 | Респайверт Лимитед | Производные n-(1-фенил-3-алкилпиразол-5-ил)-n'-арилмочевины |
NZ593104A (en) | 2008-12-11 | 2012-11-30 | Respivert Ltd | P38 map kinase inhibitors |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
ES2609767T3 (es) * | 2009-10-12 | 2017-04-24 | F. Hoffmann-La Roche Ag | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK |
CN102834009A (zh) | 2010-02-11 | 2012-12-19 | 范德比尔特大学 | 苯异唑和氮杂苯并异恶唑用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 |
TW201247650A (en) | 2011-03-16 | 2012-12-01 | Hoffmann La Roche | 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
SG11201402986RA (en) | 2011-12-09 | 2014-12-30 | Chiesi Farma Spa | Kinase inhibitors |
DK2819998T3 (da) * | 2012-03-01 | 2022-04-19 | Array Biopharma Inc | Krystallinske former af 1-(3-tert-butyl-1-P-tolyl-1H-pyrazol-5-yl)-3-(5-fluor-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)ureahydrochlorid |
EP2890380A2 (en) * | 2012-08-29 | 2015-07-08 | Merck Patent GmbH | Ddr2 inhibitors for the treatment of osteoarthritis |
CA2889466C (en) | 2012-10-12 | 2021-09-14 | Exelixis, Inc. | Novel process for making compounds for use in the treatment of cancer |
JP6433922B2 (ja) | 2013-02-27 | 2018-12-05 | アレイ バイオファーマ、インコーポレイテッド | インダゾール誘導体の調製に使用するための中間体およびその調製方法 |
EP2968322B1 (en) | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof |
EP3057934B1 (en) * | 2013-10-18 | 2019-03-27 | Blanchette Rockefeller Neurosciences, Institute | Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases |
CN104974160B (zh) * | 2014-04-08 | 2017-12-05 | 辰欣药业股份有限公司 | 2‑甲基吡唑并[1,5‑a]嘧啶‑6‑羧酸衍生物及其应用 |
WO2016114816A1 (en) * | 2015-01-18 | 2016-07-21 | Sri International | MAP4K4 (HGK) Inhibitors |
RU2675496C1 (ru) * | 2017-03-31 | 2018-12-20 | Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук | Способ получения алкиловых эфиров гидроксибензойных кислот |
CN108947879B (zh) * | 2017-05-17 | 2022-06-28 | 中国科学院上海药物研究所 | Prmt i型抑制剂及其制备方法和用途 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
SG10202110259QA (en) | 2017-10-05 | 2021-10-28 | Fulcrum Therapeutics Inc | Use of p38 inhibitors to reduce expression of dux4 |
AU2019242628A1 (en) | 2018-03-26 | 2020-09-24 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
EP4051665A1 (en) | 2019-10-28 | 2022-09-07 | Teva Pharmaceuticals International GmbH | Solid state forms of arry-797 and process for preparation thereof |
CN113354558B (zh) * | 2021-07-12 | 2022-03-11 | 无锡双启科技有限公司 | 一种2-氨基-5-氟苯腈的制备方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5998060A (ja) * | 1982-11-27 | 1984-06-06 | Fujisawa Pharmaceut Co Ltd | インダゾ−ル誘導体、その製造法および農薬 |
US4571255A (en) * | 1983-12-29 | 1986-02-18 | Ppg Industries, Inc. | Subsituted phenoxybenzisoxazole herbicides |
JPS6368568A (ja) * | 1986-09-10 | 1988-03-28 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
NZ224714A (en) * | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
IE910278A1 (en) * | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
WO1994001415A1 (en) * | 1992-07-03 | 1994-01-20 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivative and weedkiller |
AU682947B2 (en) * | 1994-05-27 | 1997-10-23 | Mochida Pharmaceutical Co., Ltd. | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity |
DE69637948D1 (de) | 1995-10-06 | 2009-07-23 | Merck & Co Inc | Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
TR199902622T2 (xx) * | 1997-04-24 | 2000-05-22 | Ortho-Mcneil Pharmaceutical, Inc. | Enflamatuvar hastal�klar�n tedavisinde faydal� ikameli imidazoller. |
AU7726898A (en) * | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
KR100378937B1 (ko) * | 1997-10-20 | 2003-05-09 | 에프. 호프만-라 로슈 아게 | 바이사이클릭 키나아제 억제제 |
JP2001521934A (ja) * | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
GB9820767D0 (en) * | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
MXPA01008440A (es) * | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
JP2002539206A (ja) * | 1999-03-12 | 2002-11-19 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての芳香族複素環化合物 |
US6358945B1 (en) * | 1999-03-12 | 2002-03-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
AU4063600A (en) * | 1999-04-05 | 2000-10-23 | Merck & Co., Inc. | A method of treating cancer |
ATE376547T1 (de) | 1999-05-21 | 2007-11-15 | Scios Inc | Derivate des indol-typs als p38 kinase inhibitoren |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
AU1899501A (en) * | 1999-11-27 | 2001-06-04 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives |
AU4890301A (en) * | 2000-04-17 | 2001-10-30 | Dong Wha Pharmaceutical Industrial Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
JP2004529859A (ja) | 2000-11-20 | 2004-09-30 | サイオス インコーポレイテッド | インドール誘導体とp38キナーゼの阻害剤としてのその使用方法 |
US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
ATE323701T1 (de) | 2001-03-09 | 2006-05-15 | Pfizer Prod Inc | Triazolopyridine als entzündungshemmende mittel |
JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
WO2003032989A1 (en) | 2001-10-18 | 2003-04-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
AU2002353186A1 (en) * | 2001-12-19 | 2003-06-30 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
WO2003087072A1 (fr) * | 2002-03-29 | 2003-10-23 | Mochida Pharmaceutical Co., Ltd. | Agent therapeutique destine a des troubles endotheliaux |
WO2004039796A1 (de) * | 2002-10-28 | 2004-05-13 | Bayer Healthcare Ag | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
WO2005004818A2 (en) * | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
ES2390459T3 (es) * | 2003-12-22 | 2012-11-13 | Eli Lilly And Company | Antagonistas de receptores de opioides |
EP1883404A4 (en) * | 2005-05-11 | 2010-03-31 | Array Biopharma Inc | P38 INHIBITORS AND METHODS OF USE |
-
2004
- 2004-02-25 RU RU2005131197/04A patent/RU2357957C2/ru active
- 2004-02-25 JP JP2006508838A patent/JP4617299B2/ja not_active Expired - Lifetime
- 2004-02-25 CA CA2517517A patent/CA2517517C/en not_active Expired - Lifetime
- 2004-02-25 MX MXPA05009459A patent/MXPA05009459A/es active IP Right Grant
- 2004-02-25 AU AU2004218463A patent/AU2004218463B2/en not_active Expired
- 2004-02-25 EP EP04714621A patent/EP1606283B1/en not_active Expired - Lifetime
- 2004-02-25 PL PL378432A patent/PL214032B1/pl unknown
- 2004-02-25 WO PCT/US2004/005693 patent/WO2004078116A2/en active Application Filing
- 2004-02-25 US US10/788,044 patent/US7521447B2/en active Active
-
2005
- 2005-09-02 KR KR1020057016417A patent/KR101099281B1/ko active IP Right Grant
- 2005-09-21 IS IS8037A patent/IS2675B/is unknown
- 2005-09-26 NO NO20054453A patent/NO328913B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004078116A2 (en) | 2004-09-16 |
JP4617299B2 (ja) | 2011-01-19 |
US20040192653A1 (en) | 2004-09-30 |
RU2005131197A (ru) | 2006-05-10 |
NO328913B1 (no) | 2010-06-14 |
CA2517517C (en) | 2012-12-18 |
EP1606283A4 (en) | 2007-05-23 |
IS8037A (is) | 2005-09-21 |
WO2004078116A9 (en) | 2008-09-12 |
NO20054453D0 (no) | 2005-09-26 |
IS2675B (is) | 2010-09-15 |
JP2006519259A (ja) | 2006-08-24 |
WO2004078116A3 (en) | 2004-10-14 |
AU2004218463B2 (en) | 2009-07-16 |
PL378432A1 (pl) | 2006-04-03 |
EP1606283A2 (en) | 2005-12-21 |
MXPA05009459A (es) | 2006-05-17 |
CA2517517A1 (en) | 2004-09-16 |
KR101099281B1 (ko) | 2011-12-26 |
RU2357957C2 (ru) | 2009-06-10 |
US7521447B2 (en) | 2009-04-21 |
AU2004218463A1 (en) | 2004-09-16 |
EP1606283B1 (en) | 2008-10-08 |
PL214032B1 (pl) | 2013-06-28 |
KR20050106484A (ko) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054453D0 (no) | P38 inhibitorer og fremgangsmater for anvendelse derav | |
DK1606283T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
NO2017017I1 (no) | umeklinidium og vilanterol | |
DK1592686T3 (da) | Gyrase-inhibitorer og anvendelser deraf | |
NO20040640L (no) | Anordning og fremgangsmate | |
NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
IS8305A (is) | Bindandi smíðar og aðferðir við notkun þeirra | |
DK2305250T3 (da) | Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer | |
NO20052524D0 (no) | Aminerte isofiavonoidderivater og anvendelse derav | |
DK1499311T3 (da) | Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer | |
NO20032220D0 (no) | Löfteverktöy II og fremgangsmåte for anvendelse av samme | |
DK1711207T3 (da) | Interferon-alpha-antistoffer og anvendelse heraf | |
DK1465615T3 (da) | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf | |
DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
IS8489A (is) | Umritunarstillar og aðferðir þeirra | |
DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
NO20050503D0 (no) | Fremgangsmate og anordning | |
EP1883404A4 (en) | P38 INHIBITORS AND METHODS OF USE | |
NO20044012D0 (no) | Fremgangsmate og et system | |
NO20055668D0 (no) | Beta-amyloidinhibitorer og anvendelse derav | |
DK1662867T3 (da) | Insekticid-forbindelser og fremgangsmåder til valg deraf | |
NO20055582D0 (no) | Preparater og fremgangsmater omfattende gastrinforbindelser | |
NO20044848D0 (no) | Anordning og fremgangsmate | |
NO20041050L (no) | Fremgmgsmate og sammensetninger |